| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
ImmunityBio Inc (NASDAQ: IBRX)
IBRX Technical Analysis
5
| As on 22nd Apr 2025 IBRX STOCK Price closed @ 2.69 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 4.99 & Strong Sell for SHORT-TERM with Stoploss of 3.99 we also expect STOCK to react on Following IMPORTANT LEVELS. |
IBRXSTOCK Price
| Open | 2.54 | Change | Price | % |
| High | 2.75 | 1 Day | 0.18 | 7.17 |
| Low | 2.54 | 1 Week | 0.23 | 9.35 |
| Close | 2.69 | 1 Month | -0.22 | -7.56 |
| Volume | 6167048 | 1 Year | -1.01 | -27.30 |
| 52 Week High 9.15 | 52 Week Low 2.32 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| NVDA | 98.89 | 2.04% |
| WNW | 2.45 | 97.58% |
| LMDX | 0.02 | 0.00% |
| TSLA | 237.97 | 4.60% |
| SXTC | 2.08 | 103.92% |
| PLUG | 0.87 | 10.13% |
| AKTS | 0.04 | 0.00% |
| INTC | 19.51 | 3.56% |
| LILM | 0.05 | 0.00% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| IBRX Daily Charts |
IBRX Intraday Charts |
Whats New @ Bazaartrend |
IBRX Free Analysis |
|
|
IBRX Important Levels Intraday
| RESISTANCE | 3.09 |
| RESISTANCE | 2.96 |
| RESISTANCE | 2.88 |
| RESISTANCE | 2.80 |
| SUPPORT | 2.58 |
| SUPPORT | 2.50 |
| SUPPORT | 2.42 |
| SUPPORT | 2.29 |
IBRX Forecast April 2025
| 4th UP Forecast | 6.89 |
| 3rd UP Forecast | 5.54 |
| 2nd UP Forecast | 4.71 |
| 1st UP Forecast | 3.88 |
| 1st DOWN Forecast | 1.5 |
| 2nd DOWN Forecast | 0.67 |
| 3rd DOWN Forecast | -0.16 |
| 4th DOWN Forecast | -1.51 |
IBRX Weekly Forecast
| 4th UP Forecast | 4.93 |
| 3rd UP Forecast | 4.21 |
| 2nd UP Forecast | 3.77 |
| 1st UP Forecast | 3.32 |
| 1st DOWN Forecast | 2.06 |
| 2nd DOWN Forecast | 1.61 |
| 3rd DOWN Forecast | 1.17 |
| 4th DOWN Forecast | 0.45 |
IBRX Forecast2025
| 4th UP Forecast | 18.59 |
| 3rd UP Forecast | 13.49 |
| 2nd UP Forecast | 10.34 |
| 1st UP Forecast | 7.19 |
| 1st DOWN Forecast | -1.81 |
| 2nd DOWN Forecast | -4.96 |
| 3rd DOWN Forecast | -8.11 |
| 4th DOWN Forecast | -13.21 |
ImmunityBio Inc ( NASDAQ USA Symbol : IBRX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
IBRX Business Profile
ImmunityBio, Inc., a clinical-stage immunotherapy company, develops cell and immune therapies to treat cancers and infectious diseases. The company develops Anktiva (N-803), an IL-15 superagonist and PD-L1 that activates natural killer and T effector cells in combination with chemo and trodelvy to treat cancers, such as merkel cell carcinoma, advanced pancreatic cancer, and advanced triple negative breast cancer; and an albumin-linked formulation of doxorubicin (Aldoxorubicin) to treat breast cancer, hodgkin lymphoma, SCLC, sarcoma, and glioblastoma. It also develops a memory T-cell cancer vaccine to deliver tumor-associated antigens and neoepitopes; and a human adenovirus 5 COVID-19 vaccine. The company was founded in 2014 and is based in San Diego, California. Address: 3530 John Hopkins Court, San Diego, CA, United States, 92121
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service